12 Years of Prestigious Science Behind Genetically Guided Nuturtion
Lilyana Lovela, Independent Affiliate asked:
r/>
World Class Scientific Group
GeneWize’s impeccably credentialed scientific group is comprised of leading scientists and researchers in the fields of biotechnology, genomics, molecular biology, chemistry, medicine, clinical laboratory medicine and nutritional sciences.
As a group, they have over 600 peer reviewed publications and abstracts, numerous awards, dozens of patents and distinguished careers with some of the world’s foremost public and private biosciences corporations, as well as universities.
GENELINK SCIENTIFIC ADVISORY BOARD
Robert Ricciardi, Ph.D. Chief Scientific Officer
Dr. Robert Ricciardi is a Professor of Microbiology at the University of Pennsylvania, where he is Chairman of the Microbiology and Virology Program of the Molecular Biology Graduate Group. He received his Ph.D. from the University of Illinois at Urbana in cellular biology. He was a postdoctoral fellow at Brandeis University and Harvard Medical School in the Department of Biological Chemistry and was forwarded fellowships by the American Cancer Society,
National Institutes of Health and Charles A. King Trust. He developed one of the first techniques in molecular biology, which has been widely used both to map genes and determine the proteins they encode. While most of his research has centered on basic mechanisms of cancer, he has developed, patented, and has a patent pending for recombinant delivery vectors for use as vaccines and for potential use in gene therapy. Dr. Ricciardi has served as a consultant to The National Department of Infectious Disease. He has authored 55 publications, has been awarded a NATO Visiting Professorship at Ferrara Medical School, Italy, and has been an invitational speaker at various scientific meetings and a seminar guest speaker at the Mayo Clinic and Johns
Hopkins University.
Dr. Bernard L. Kasten, Chief Medical Officer
Dr. Kasten is the Executive Chairman of the Board of GeneLink Inc. Companies and serves as Chief Medical Officer of GeneWize Lifesciences. Dr. Kasten has been a scientific advisor to the Company since 1999 and a member of the Company’s Advisory Committee since 2001. Dr. Kasten is a graduate of Miami University (Oxford Ohio), BA Chemistry 1967, and the Ohio State University College of Medicine MD 1971. Dr. Kasten is a Diplomat of the American Board of Pathology with Certification in Anatomic and Clinical Pathology with sub-specialty certification in Medical Microbiology. Dr. Kasten is an author of “Infectious Disease Handbook” 1st through 5th Editions 1994-2003 and the “Laboratory Test Handbook” 1st through 4th Editions 1984-1996 published by Lexi-Comp Inc., Hudson, Ohio. Dr. Kasten received the College of American Pathologists Presidents Medal Awarded for Outstanding Service in 1989 and the College of American Pathologists Frank W. Hartman Award, in 1993 for Meritorious Service to the College. Dr. Kasten’s professional staff appointments have included the Cleveland Clinic, Northeastern Ohio Universities College of Medicine, the Bethesda Hospitals and Quest Diagnostics. Dr. Kasten served eight years, 1996-2004, at Quest Diagnostics Incorporated [NYSE-DGX], where he was Chief Laboratory Officer; Vice-President of Business Development for Science and Medicine and Vice-President of Medical Affairs of a Quest Diagnostics wholly-owned subsidiary, MedPlus Inc. Fort Worth.
FOR MORE INFORMATION CLICK HERE
GENELINK SCIENTIFIC ADVISORY BOARD
Robert Kagan, M.D., F.A.C.P.
Dr. Kagan is Board Certified in Clinical Pathology, Nuclear Medicine and Hyperbaric Medicine. He received his medical degree from Georgetown University School of Medicine. His postgraduate medical education included a medical internship at the University of California San Francisco and residency training programs in Pathology and Nuclear Medicine at the National Institute of Health. He completed fellowships in MRI at UC-San Francisco and Huntington Memorial Research Laboratories in Pasadena. He is Past President of the Florida Association of Nuclear Physicians and Past Chairman of the Board of the Nuclear Medicine Resource Committee of the College of American Pathologists.
Dr. Kagan is again on the cutting edge of science. He is the Medical Director of BodyView, the first full body scanning facility to offer a programmatic approach to healthcare. Prior to opening the first outpatient MRI center in Florida, Dr. Kagan was the Medical Director of Nuclear Medicine at Holy Cross Hospital in Fort Lauderdale and Clinical Assistant Professor of Radiology at the University of Miami. Dr. Kagan has published many papers in peer reviewed medical journals and has been an invited lecturer nationally and internationally in Magnetic Resonance Imaging and Nuclear Medicine. He is a member of numerous medical societies including the Radiologic Society of North America, the Society of Magnetic Resonance in Medicine, the International Society of Magnetic Resonance Imaging, the Institute for Clinical PET American College of Nuclear Physicians, the College of American Pathologists, Society for Clinical Magnetic Resonance Imaging, and the American Roentgen Ray Society.
James W. Simpkins, Ph.D.
Dr. James W. Simpkins received his B.S., and M.S. degrees from the University of Toledo and in 1977 received a Ph.D. Degree in Physiology from Michigan State University. He joined the faculty at the University of Florida, College of Pharmacy in 1997 and rose through the ranks to the position of Professor of Pharmacodynamics.
He has served as Chairman of the Department of Pharmacodynamics, Chairman of the Department of Pharmaceutics, Associate Dean for Research and Graduate Studies and Director, Center for the Neurobiology of Aging at the University of Florida. In 1996, Dr. Simpkins was appointed as the Frank Duckworth Professor of Drug Discovery at the University of Florida. He has more than 295 peer-reviewed publications, a dozen patents for his discoveries and has edited two texts on Alzheimer’s disease therapy. He also served as the Director of the University of Florida Drug Discovery Group for Alzheimer’s disease, which has sustained funding by the National Institute on Aging to support research in the pharmacotherapy for Alzheimer’s disease. In 1999 he was appointed to the Medical and Scientific Advisory Council of the National Alzheimer’s Association. In July of 2000, he became the Chair of the Department of Pharmacology and Neuroscience and Director, Institute for Aging and Alzheimer’s disease Research at the University of North Texas Health Science at Fort Worth.
GENELINK SCIENTIFIC ADVISORY BOARD
Robert P.K. Keller, M.D.
Dr. Keller is Founder and Medical Director of The Keller Medical Institute. Dr. Keller began his distinguished career in medicine over 30 years ago and has been a respected member of the Monterey Peninsula medical community for 21 years. Residency trained as a trauma physician and surgeon, he began repairing damaged skin in the late 1970’s. Wanting to become more proactive in skin repair, he took post-doctorate studies in cosmetic and anti-aging medicine and trained with some of the world’s most renowned physicians. A former nationally syndicated television medical news commentator, Dr. Keller has lectured internationally and is listed in the 2001 National Registry of Who’s Who. His patient list includes many of the most celebrated names in sports, entertainment and business.
Harold H. Harrison M.D., Ph.D., FCAP Medical Director
Dr. Harrison has served as Corporate Medical Director of Genetic Services for Quest Diagnostics,and as overall Medical Director for the biochemical, molecular, cytogenetic, and HLA laboratories of Genetrix, Inc., a national genetic services company that was acquired by GenzymeGenetics in 1997. A Clinical Pathologist with subspecialty training in all areas of genetic services and a Ph.D. in biochemical genetics, Dr. Harrison is a Fellow of the College of American Pathologists and a member of the American College of Medical Genetics and American Society of Human Genetics. He holds medical licenses in six states (AZ, CA, IL, NJ, NV, and NY), and laboratory director’s licensure in NJ and NY. A former faculty member at the Univ. of Chicago Pritzker School of Medicine, Dr. Harrison has 80 publications and abstracts, and several OMIM/GDB citations for his and collaborators’ genetic discoveries.
Dr. Harrison currently holds a clinical faculty appointment with the Univ. of Arizona Medical School.
Donald J. Cannon, Ph.D.
Dr. Cannon received his A.B. in Chemistry from Harvard College and a M.A. in Medical Sciences and a Ph.D in Biochemistry from Boston University. He has been on the faculty at the Medical Schools at the University of Hawaii, University of Arkansas, and Marshall University where he has lectured to medical, graduate, nursing and allied health students and was director of the Pathology residency program at Marshall University. He has directed laboratories and performed research at the Boston Biomedical Research Institute, the Little Rock, Arkansas VAMC and the Bethesda Hospitals in Cincinnati. Dr. Cannon has served as Laboratory Director in Forensic Toxicology, National Manager of Operations Excellence and National Manager of Special Projects in Business Ventures at Quest Diagnostics. He has over 130 publications and book chapters, and is an active member of the American Association for Clinical Chemistry, the Association of Clinical Scientists and the National Academy of Clinical Biochemistry. He has been invited and has continued to lecture on a number of topics in various countries and locales. Dr. Cannon has received numerous awards related to clinical laboratory medicine, laboratory management and teaching. He is currently Professor of Chemistry and Director of the Forensic Sciences program at the University of Tampa.
GeneLink Biosciences, Inc., the parent company’s developmental pipeline incorporates important Medical and Pharmacogenomic research areas such as genetic assessments for early the detection of Alzheimer’s and Dementia, Cardiovascular Disease, Metabolic Syndrome and innovative methods for DNA collection.
Pioneering technologies for over a decade
On May 1st, 2007, GeneWize’s parent company, GeneLink, Inc. was granted a U.S. Patent for “Kits and Methods for Assessing Skin Health” — the third patent to be granted from a family of patent applications filed by GeneLink in the U.S. and abroad.
GeneLink, Inc. is the first (and only) company to be granted a patent for a therapeutic skin health regimen linked to DNA-based skin health assessment. Tens of thousands of people have used these products and they have been available to many healthcare professionals to use in their practice since 2004.
A partial list of national and international patents (and patents pending) includes: Kits and Methods for Assessing Oxidative Stress; Kits and Methods for Assessing Cardiovascular Health; Kits and Methods for Assessing Bone Health; and, Kits and Methods for Assessing Coenzyme Q Reducing Status.
To support its vision, GeneLink has launched GeneWize Life Sciences to further develop an impressive portfolio of DNA-based assessments personalizing proprietary systems direct to the consumer, including: (See Products )
Oxidative Stress Assessment Comprehensive Cardio Assessment Lipid Metabolism Assessment Bone Density Assessment Healthy Aging Assessment Nutragenetic Assessment CoQ10 Efficiency Assessment Skin Health Assessment (also know as Dermagenetics® Skin Health Assessment) Dermagenetics® Customized Skin Care System Nutragenetics Customized Nutritional Supplement System DNA Collection System
FOR MORE INFORMATION CLICK HERE
GeneWize Life Sciences — Building the Healthiest Families on Earth
Simply stated, GeneWize Life Sciences’ mission is to:
-Help people achieve their best possible health futures; and
-Help them look better, feel better and live longer, healthier lives..
Kansieo.com
This entry was posted
on Monday, January 5th, 2009 at 6:38 pm and is filed under Anti Aging.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
r/>
World Class Scientific Group
GeneWize’s impeccably credentialed scientific group is comprised of leading scientists and researchers in the fields of biotechnology, genomics, molecular biology, chemistry, medicine, clinical laboratory medicine and nutritional sciences.
As a group, they have over 600 peer reviewed publications and abstracts, numerous awards, dozens of patents and distinguished careers with some of the world’s foremost public and private biosciences corporations, as well as universities.
GENELINK SCIENTIFIC ADVISORY BOARD
Robert Ricciardi, Ph.D. Chief Scientific Officer
Dr. Robert Ricciardi is a Professor of Microbiology at the University of Pennsylvania, where he is Chairman of the Microbiology and Virology Program of the Molecular Biology Graduate Group. He received his Ph.D. from the University of Illinois at Urbana in cellular biology. He was a postdoctoral fellow at Brandeis University and Harvard Medical School in the Department of Biological Chemistry and was forwarded fellowships by the American Cancer Society,
National Institutes of Health and Charles A. King Trust. He developed one of the first techniques in molecular biology, which has been widely used both to map genes and determine the proteins they encode. While most of his research has centered on basic mechanisms of cancer, he has developed, patented, and has a patent pending for recombinant delivery vectors for use as vaccines and for potential use in gene therapy. Dr. Ricciardi has served as a consultant to The National Department of Infectious Disease. He has authored 55 publications, has been awarded a NATO Visiting Professorship at Ferrara Medical School, Italy, and has been an invitational speaker at various scientific meetings and a seminar guest speaker at the Mayo Clinic and Johns
Hopkins University.
Dr. Bernard L. Kasten, Chief Medical Officer
Dr. Kasten is the Executive Chairman of the Board of GeneLink Inc. Companies and serves as Chief Medical Officer of GeneWize Lifesciences. Dr. Kasten has been a scientific advisor to the Company since 1999 and a member of the Company’s Advisory Committee since 2001. Dr. Kasten is a graduate of Miami University (Oxford Ohio), BA Chemistry 1967, and the Ohio State University College of Medicine MD 1971. Dr. Kasten is a Diplomat of the American Board of Pathology with Certification in Anatomic and Clinical Pathology with sub-specialty certification in Medical Microbiology. Dr. Kasten is an author of “Infectious Disease Handbook” 1st through 5th Editions 1994-2003 and the “Laboratory Test Handbook” 1st through 4th Editions 1984-1996 published by Lexi-Comp Inc., Hudson, Ohio. Dr. Kasten received the College of American Pathologists Presidents Medal Awarded for Outstanding Service in 1989 and the College of American Pathologists Frank W. Hartman Award, in 1993 for Meritorious Service to the College. Dr. Kasten’s professional staff appointments have included the Cleveland Clinic, Northeastern Ohio Universities College of Medicine, the Bethesda Hospitals and Quest Diagnostics. Dr. Kasten served eight years, 1996-2004, at Quest Diagnostics Incorporated [NYSE-DGX], where he was Chief Laboratory Officer; Vice-President of Business Development for Science and Medicine and Vice-President of Medical Affairs of a Quest Diagnostics wholly-owned subsidiary, MedPlus Inc. Fort Worth.
FOR MORE INFORMATION CLICK HERE
GENELINK SCIENTIFIC ADVISORY BOARD
Robert Kagan, M.D., F.A.C.P.
Dr. Kagan is Board Certified in Clinical Pathology, Nuclear Medicine and Hyperbaric Medicine. He received his medical degree from Georgetown University School of Medicine. His postgraduate medical education included a medical internship at the University of California San Francisco and residency training programs in Pathology and Nuclear Medicine at the National Institute of Health. He completed fellowships in MRI at UC-San Francisco and Huntington Memorial Research Laboratories in Pasadena. He is Past President of the Florida Association of Nuclear Physicians and Past Chairman of the Board of the Nuclear Medicine Resource Committee of the College of American Pathologists.
Dr. Kagan is again on the cutting edge of science. He is the Medical Director of BodyView, the first full body scanning facility to offer a programmatic approach to healthcare. Prior to opening the first outpatient MRI center in Florida, Dr. Kagan was the Medical Director of Nuclear Medicine at Holy Cross Hospital in Fort Lauderdale and Clinical Assistant Professor of Radiology at the University of Miami. Dr. Kagan has published many papers in peer reviewed medical journals and has been an invited lecturer nationally and internationally in Magnetic Resonance Imaging and Nuclear Medicine. He is a member of numerous medical societies including the Radiologic Society of North America, the Society of Magnetic Resonance in Medicine, the International Society of Magnetic Resonance Imaging, the Institute for Clinical PET American College of Nuclear Physicians, the College of American Pathologists, Society for Clinical Magnetic Resonance Imaging, and the American Roentgen Ray Society.
James W. Simpkins, Ph.D.
Dr. James W. Simpkins received his B.S., and M.S. degrees from the University of Toledo and in 1977 received a Ph.D. Degree in Physiology from Michigan State University. He joined the faculty at the University of Florida, College of Pharmacy in 1997 and rose through the ranks to the position of Professor of Pharmacodynamics.
He has served as Chairman of the Department of Pharmacodynamics, Chairman of the Department of Pharmaceutics, Associate Dean for Research and Graduate Studies and Director, Center for the Neurobiology of Aging at the University of Florida. In 1996, Dr. Simpkins was appointed as the Frank Duckworth Professor of Drug Discovery at the University of Florida. He has more than 295 peer-reviewed publications, a dozen patents for his discoveries and has edited two texts on Alzheimer’s disease therapy. He also served as the Director of the University of Florida Drug Discovery Group for Alzheimer’s disease, which has sustained funding by the National Institute on Aging to support research in the pharmacotherapy for Alzheimer’s disease. In 1999 he was appointed to the Medical and Scientific Advisory Council of the National Alzheimer’s Association. In July of 2000, he became the Chair of the Department of Pharmacology and Neuroscience and Director, Institute for Aging and Alzheimer’s disease Research at the University of North Texas Health Science at Fort Worth.
GENELINK SCIENTIFIC ADVISORY BOARD
Robert P.K. Keller, M.D.
Dr. Keller is Founder and Medical Director of The Keller Medical Institute. Dr. Keller began his distinguished career in medicine over 30 years ago and has been a respected member of the Monterey Peninsula medical community for 21 years. Residency trained as a trauma physician and surgeon, he began repairing damaged skin in the late 1970’s. Wanting to become more proactive in skin repair, he took post-doctorate studies in cosmetic and anti-aging medicine and trained with some of the world’s most renowned physicians. A former nationally syndicated television medical news commentator, Dr. Keller has lectured internationally and is listed in the 2001 National Registry of Who’s Who. His patient list includes many of the most celebrated names in sports, entertainment and business.
Harold H. Harrison M.D., Ph.D., FCAP Medical Director
Dr. Harrison has served as Corporate Medical Director of Genetic Services for Quest Diagnostics,and as overall Medical Director for the biochemical, molecular, cytogenetic, and HLA laboratories of Genetrix, Inc., a national genetic services company that was acquired by GenzymeGenetics in 1997. A Clinical Pathologist with subspecialty training in all areas of genetic services and a Ph.D. in biochemical genetics, Dr. Harrison is a Fellow of the College of American Pathologists and a member of the American College of Medical Genetics and American Society of Human Genetics. He holds medical licenses in six states (AZ, CA, IL, NJ, NV, and NY), and laboratory director’s licensure in NJ and NY. A former faculty member at the Univ. of Chicago Pritzker School of Medicine, Dr. Harrison has 80 publications and abstracts, and several OMIM/GDB citations for his and collaborators’ genetic discoveries.
Dr. Harrison currently holds a clinical faculty appointment with the Univ. of Arizona Medical School.
Donald J. Cannon, Ph.D.
Dr. Cannon received his A.B. in Chemistry from Harvard College and a M.A. in Medical Sciences and a Ph.D in Biochemistry from Boston University. He has been on the faculty at the Medical Schools at the University of Hawaii, University of Arkansas, and Marshall University where he has lectured to medical, graduate, nursing and allied health students and was director of the Pathology residency program at Marshall University. He has directed laboratories and performed research at the Boston Biomedical Research Institute, the Little Rock, Arkansas VAMC and the Bethesda Hospitals in Cincinnati. Dr. Cannon has served as Laboratory Director in Forensic Toxicology, National Manager of Operations Excellence and National Manager of Special Projects in Business Ventures at Quest Diagnostics. He has over 130 publications and book chapters, and is an active member of the American Association for Clinical Chemistry, the Association of Clinical Scientists and the National Academy of Clinical Biochemistry. He has been invited and has continued to lecture on a number of topics in various countries and locales. Dr. Cannon has received numerous awards related to clinical laboratory medicine, laboratory management and teaching. He is currently Professor of Chemistry and Director of the Forensic Sciences program at the University of Tampa.
GeneLink Biosciences, Inc., the parent company’s developmental pipeline incorporates important Medical and Pharmacogenomic research areas such as genetic assessments for early the detection of Alzheimer’s and Dementia, Cardiovascular Disease, Metabolic Syndrome and innovative methods for DNA collection.
Pioneering technologies for over a decade
On May 1st, 2007, GeneWize’s parent company, GeneLink, Inc. was granted a U.S. Patent for “Kits and Methods for Assessing Skin Health” — the third patent to be granted from a family of patent applications filed by GeneLink in the U.S. and abroad.
GeneLink, Inc. is the first (and only) company to be granted a patent for a therapeutic skin health regimen linked to DNA-based skin health assessment. Tens of thousands of people have used these products and they have been available to many healthcare professionals to use in their practice since 2004.
A partial list of national and international patents (and patents pending) includes: Kits and Methods for Assessing Oxidative Stress; Kits and Methods for Assessing Cardiovascular Health; Kits and Methods for Assessing Bone Health; and, Kits and Methods for Assessing Coenzyme Q Reducing Status.
To support its vision, GeneLink has launched GeneWize Life Sciences to further develop an impressive portfolio of DNA-based assessments personalizing proprietary systems direct to the consumer, including: (See Products )
Oxidative Stress Assessment Comprehensive Cardio Assessment Lipid Metabolism Assessment Bone Density Assessment Healthy Aging Assessment Nutragenetic Assessment CoQ10 Efficiency Assessment Skin Health Assessment (also know as Dermagenetics® Skin Health Assessment) Dermagenetics® Customized Skin Care System Nutragenetics Customized Nutritional Supplement System DNA Collection System
FOR MORE INFORMATION CLICK HERE
GeneWize Life Sciences — Building the Healthiest Families on Earth
Simply stated, GeneWize Life Sciences’ mission is to:
-Help people achieve their best possible health futures; and
-Help them look better, feel better and live longer, healthier lives..
Kansieo.com
Leave a Reply